Tonight at 6pm, the ASCO abstracts of live online with the exception of the plenaries, late breakers and clinical review abstracts, which will published at the meeting.  7 policy exceptions were granted under SEC guidelines, meaning that limited information to be made publicly available in advance of the meeting:

Abstract 8010: Lenalidomide maintenance after transplantation for myeloma. 

Abstract LBA4007: The AVAGAST trial: A randomized, double-blind, placebo-controlled, multicenter phase III study of capecitabine and cisplatin plus bevacizumab or placebo as first-line therapy in patients with advanced gastric cancer. 

Abstract LBA4507: Denosumab versus zoledronic acid for treatment of bone metastases in patients with castration-resistant prostate cancer. 

Abstract LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. 

Abstract LBA4511: A randomized, double-blind, placebo controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castrate-resistant prostate cancer (metCRPC): Survival results of CALGB 90401. 

Abstract LBA7502: Results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGPR-inhibitor naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 

Abstract LBA8512: A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma.

Of these 7, no doubt keen investors will be interested in the first ($CELG) and last ($DCTH), and analysts will be anxious to see the denosumab data ($AMGN), but the ones that I will be most interested in are ARQ197 ($ARQL) and bevacizumab (Avastin) ($RHHYG).  We already know that the Avastin data was negative in gastric and prostate cancers, but positive in ovarian cancer from Roche's previous press announcements.  Ovarian cancer badly needs new options that improve outcomes for women suffering with the disease.

Sometimes though, the best data is not always in the plenary session, witness the Herceptin trial in adjuvant HER2+ breast cancer a few years ago when everyone stood up in a packed session and clapped because the data was simply stunning and groundbreaking. 

Tonight's peek at the available abstracts should give us some clues about what might be interesting. I'll try and schedule some quick posts this evening as I'll be out at client meetings all day tomorrow, great timing, not.